Status:
ACTIVE_NOT_RECRUITING
Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)
Lead Sponsor:
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Conditions:
Polycythemia Vera
Eligibility:
All Genders
18-100 years
Brief Summary
Polycythaemia vera (PV) is associated with a reduced quality of life, a high rate of vascular events, and an intrinsic risk of disease evolution. The results of several randomised trials for the treat...
Detailed Description
Classical Philadelphia-negative myeloproliferative neoplasms (Ph-neg MPNs) including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) are characterized by uncontrolled cl...
Eligibility Criteria
Inclusion
- Patients diagnosed with Polycythemia Vera by WHO 2016
- Patient aged ≥ 18 years old
- Patients in need of cytoreductive treatments with ropeginterferon alfa-2b in first or later lines according to the reimbursability criteria defined by the Italian National Health System
- Patients who have signed the written informed consent for study participation.
Exclusion
- • Any contraindication for ropeginterferon alfa-2b according to the SmPC
Key Trial Info
Start Date :
September 8 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
319 Patients enrolled
Trial Details
Trial ID
NCT06506084
Start Date
September 8 2022
End Date
December 31 2026
Last Update
December 26 2025
Active Locations (37)
Enter a location and click search to find clinical trials sorted by distance.
1
UOC Ematologia, ASST Papa Giovanni XXIII
Bergamo, Lombardy, Italy, 24127
2
Divisione Ematologia ASST, Grande Ospedale Metropolitano Niguarda
Milan, Lombardy, Italy, 20162
3
Divisione Ematologia, Fondazione IRCCS Policlinico San Matteo
Pavia, Lombardy, Italy, 27100
4
U.O. Ematologia, Ospedale di Circolo e Fondazione Macchi Varese
Varese, Lombardy, Italy, 21100